Appointment of Non-Executive Director

PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart phone-based pain assessment and monitoring application, is pleased to announce the appointment of Ms. Cynthia Payne as a Non-Executive Director, effective 30 March 2022.

Ms. Payne brings 30 years executive leadership experience as well as significant board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a large private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a leading consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices.

Ms. Payne is currently a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia. Ms. Payne holds a Bachelor of Applied Science (Nursing) with specific interest in Dementia Care, an MBA from the University of New England, is a Member of the Australian Institute of Company Directors, Fellow of the Governance Institute Australia and Certified Chair with The Board Advisory centre.

PainChek's Chairman John Murray said: "We are delighted to welcome Cynthia to the Board of Directors. She brings deep operational and clinical expertise in residential and home care aged care sectors, where she is widely known and respected, and these sectors are key global market opportunities for the Company. Cynthia's depth of experience will complement and further strengthen the Board and its diversity."

This announcement has been authorized for release by the Board of PainChek.

For more information:

Sally McDow	Philip Daffas
Company Secretary, PainChek	CEO, PainChek
sally.mcdow@boardroomlimited.com.au	philip.daffas@painchek.com
0420 213 035	0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

ABN 21 146 035 127   **P:** +61 1800 098 809
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 1

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants' products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore, and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

ABN 21 146 035 127   **P:** +61 8 1800 098 809
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 2